Herbalife opened lower at $15.52, compared with its previous close of $15.55. In the last trading session, the stock traded between $15.09 and $15.63. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Herbalife is now worth
$ 36.67
Resulting in a loss of
$ 63.33 (63.33%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
0%
Sell
25%
Markets Today
Today's Change
$-0.34 (-2.17%)
Day High
$15.63
Day Low
$15.09
Day Open
$15.52
Prev Close
$15.55
Volume
8,22,154
1W Return
-0.41%
1M Return
11.62%
3M Return
29.43%
6M Return
12.61%
1Y Return
67.91%
Fundamentals
Market Cap ($ Mn)
1,596
PE Ratio
7.92
PB Ratio
-
PEG Ratio
2.01
ROE
-
ROCE
29.45%
EPS (TTM)
$0.56
Investment Returns
1 Week
-0.41%
1 Month
11.62%
3 Months
29.43%
6 Months
12.61%
9 Months
-8.13%
Financials
Quarterly
All values in $ Mn
1.3K
Jun 25
1.3K
Sep 25
1.3K
Dec 25
1.3K
Mar 26
1.3K
Jun 26
1.4K
Sep 26
Updates
11Nov
Argus Research maintains Buy on Herbalife, lifts price target to $20
Argus Research maintains a Buy rating on Herbalife. Price target raised from $15 to $20. Analyst John Staszak issued the updated recommendation.
Yesterday
3Nov
Herbalife Q3FY26 Results: Net sales up 6% YoY to $1.4 billion
Raised FY26 net sales guidance to $5.285 billion-$5.335 billion, beating $5.255 billion estimate. Q3FY26 net sales rose 6% YoY to $1.4 billion, exceeding guidance. Adjusted EBITDA reached $182 million with margin expanding 70 bps to 13.5%. Asia Pacific constant currency sales grew 26%, driven by 39% increase in India.
10 days ago
8Sep
Herbalife authorizes $250 million share repurchase program
Herbalife authorized a $250 million share repurchase program over three years. Shares rose 2.67% to $12.71 following the announcement. CFO John DeSimone cited strong free cash flow and attractive share valuation. Management will host a fireside chat at the Barclays Global Consumer Conference on September 9, 2026.
2mo ago
1Sep
Johnson Fistel probes Herbalife over CEO exit and stock drop
Johnson Fistel investigates Herbalife Ltd. over CEO Stephan Gratziani's departure. Stock fell 11.6% on August 31 after Gratziani left to focus on distributorship. Probe examines disclosure of $5 million annual payouts from Gratziani's network. CFO John DeSimone named interim CEO with no permanent successor identified.
2mo ago
31Aug
Herbalife reaffirms Q3 and FY26 net sales growth guidance
Herbalife reaffirms Q3 2026 net sales growth of 0.5% to 4.5% YoY. Full-year 2026 net sales growth guidance stands at 2.5% to 5.5%. Adjusted EBITDA target for Q3 is $160 million to $180 million. Management expects fifth consecutive quarter of YoY sales growth.
2mo ago
31Aug
Herbalife CEO Gratziani to step down in Oct 2026; CFO takes interim role
Stephan Gratziani to step down as Herbalife CEO effective October 31, 2026. CFO John DeSimone named interim CEO starting November 1, 2026. Gratziani will continue as consultant focused on strategy and business development. He will refocus on his independent distributorship of nearly 700,000 distributors.
